About
Autologous cancer vaccine
Areas of Focus
Categories
VaccineMidwest
Team (25)
Alexander M. Hurst, J.D./M.B.A.
Immunophotonics
team_member
Bobby W. Sandage, Jr., Ph.D.
Immunophotonics
team_member
Daniel Von Hoff, M.D., F.A.C.P.
Immunophotonics
team_member
David Smoller, Ph.D.
Immunophotonics
team_member
David W. Anderson, Ph.D.
Immunophotonics
team_member
Diane M. Beatty, Ph.D.
Immunophotonics
team_member
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
1
As Collaborator
2
Total Enrollment
190
By Phase
PHASE1/PHASE2: 3
By Status
ACTIVE_NOT_RECRUITING: 2RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT06630624Collaborator
Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM
PHASE1/PHASE2Recruiting
120 participants
Started: Jul 10, 2024 · Completed: Aug 1, 2031
NCT05688280Lead Sponsor
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
PHASE1/PHASE2Active, not recruiting
42 participants
Started: Nov 29, 2022 · Completed: Feb 28, 2025
NCT03993678Collaborator
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
PHASE1/PHASE2Active, not recruiting
28 participants
Started: Oct 12, 2020 · Completed: Dec 31, 2025
Locations (1)
Headquarters
St. Louis, MO, United States
Map
Loading map...